A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases

Itchins, M; Ainsworth, H; Alexander, M; Dean, S; Dharmaraj, D; Pavlakis, N; Clarke, SJ; Brown, C; Torres, J; Saqib, A; Ladwa, R; O&#39;Byrne, K; Moore, M; Yip, PY; Solomon, B; John, T; Kao, S; Mitchell, P; Parakh, S

Author(s): Itchins, M; Ainsworth, H; Alexander, M; Dean, S; Dharmaraj, D; Pavlakis, N; Clarke, SJ; Brown, C; Torres, J; Saqib, A; Ladwa, R; O'Byrne, K; Moore, M; Yip, PY; Solomon, B; John, T; Kao, S; Mitchell, P; Parakh, S;
Details: Publication Year 2022-12,Volume 23,Issue #8,Page 702-708
Journal Title: Clinical Lung Cancer
Publication Type: Research article
Abstract: BACKGROUND: There are limited real world data on the IMpower150 regimen in oncogene driven tumors and central nervous system metastases; this study aims to address this gap. MATERIALS AND METHODS: Retrospective analysis of patients with advanced non-small cell lung cancer treated with the IMpower150 regimen across 12 Australian sites between July 2018 and April 2021. Clinicopathologic and treatment parameters were correlated with efficacy and toxicity. RESULTS: A total of 106 patients identified with median follow up of 8 months (range 0-72). Median age was 61 years (range 33-83), 34% Asian and 58% never-smokers. An oncogene was reported in 94 (89%) patients, EGFR in 72 (68%). At treatment commencement, 50 (47%) patients had brain metastases, 21 (20%) leptomeningeal disease (LMD) and 47 (44%) liver metastases. 27% were treatment-naive and pemetrexed was substituted for paclitaxel in 44 (42%). The overall response rate was 51% for all patients; 52% in patients with EGFR mutations. Patients with untreated brain metastases prior to commencing IMpower150 had a similar intracranial response as those with treated brain metastases (55% vs. 53%). The median time to treatment failure and overall survival from commencement of IMpower150 was 5.7 and 11.4 months respectively for the entire cohort and 5.2 and 10.5 months in those with an EGFR sensitizing mutation. Overall survival in patients with liver, brain metastases and LMD was 11.0, 11.4, and 7.1 months respectively. No new safety signals seen. CONCLUSION: In this largely oncogene positive, pre-treated population the IMpower150 regimen demonstrated clinically-meaningful responses, including in patients with CNS disease.
Keywords: Humans; Adult; Middle Aged; Aged; Aged, 80 and over; *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics; ErbB Receptors/genetics; *Lung Neoplasms/drug therapy/genetics; Retrospective Studies; Australia; *Central Nervous System Neoplasms/drug therapy/genetics; Mutation/genetics; *Brain Neoplasms/drug therapy/genetics/pathology; Oncogenes; *Neoplasms, Second Primary/genetics; Protein Kinase Inhibitors; Efficacy; IMPower150; Real world; Toxicity
Department(s): Pharmacy; Medical Oncology
PubMed ID: 36030187
Publisher's Version: https://doi.org/10.1016/j.cllc.2022.07.016
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-12-13 06:39:40

Last Modified: 2024-12-13 06:40:15